SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
Of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2002
INTERLEUKIN GENETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-23413 94-3123681
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
135 Beaver Street, Waltham, MA 02452
-------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (781) 398-0700
--------------
Item 5. Other Events.
On September 3, 2002, Interleukin Genetics, Inc. publicly disseminated a press
release announcing a letter of intent with a consumer products company and a
conference call on Thursday, September 5, 2002 at 9 a.m., eastern time, to
discuss the announcement.
The information contained in the press release is incorporated herein by
reference and filed as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(c) Exhibit
99.1 Press Release dated September 3, 2002
Exhibit 99.1
INTERLEUKIN GENETICS SIGNS LETTER OF INTENT TO ENTER INTO PRODUCT
DEVELOPMENT AND DISTRIBUTION ALLIANCE
WALTHAM, MA - September 3, 2002 - Interleukin Genetics, Inc. (NASDAQ: ILGN)
today announced it has signed a letter of intent with an undisclosed major
Consumer Products company to develop and market proprietary genomics-based
nutritional and skincare products in a worldwide nutrition market currently
valued over $40 Billion and growing at an 8% rate each year.
The two parties have executed a letter of intent that, in exchange for an
undisclosed sum, permits the nutrition company a limited period in which to
evaluate the option of entering into a joint venture or executing a licensing
agreement in the area of nutritional genomics. The arrangement allows ILGN to
continue its business development activities for the diagnostic and therapeutic
applications of the company's technology.
Many common chronic diseases, such as heart disease and Alzheimer's Disease,
have a major inflammatory component. Individuals with genetic variations covered
by ILGN's patents have more systemic inflammation and are at increased risk for
such diseases. Nutritional products designed to reduce the type of inflammation
caused by ILGN genetic variations may be an ideal approach to preventing or
delaying the onset of these chronic diseases.
"Interleukin Genetics is pleased with the progress both companies have made in
constructing a mutually beneficial business relationship. The end goal is to
co-develop and distribute nutritional supplements and skincare products using
ILGN's expertise and intellectual property in the functional genomics of
inflammation. The nutrition company has worldwide distribution and manufacturing
capabilities," said Philip Reilly, M.D., the Chairman and CEO of Interleukin
Genetics.
Interleukin Genetics will hold a conference call on Thursday, September 5, 2002,
at 9 am, eastern time to discuss this announcement. Phil Reilly, Chief Executive
Officer, and Ken Kornman, Chief Scientific Officer, will lead the call.
CONFERENCE CALL INFORMATION
Date: Thursday, September 5, 2002
Time: 9 a.m., eastern time
Toll-Free: (800) 946-0782
There will be a replay of the conference call for 24 hours, which can be
accessed in the United States by dialing toll-free (888) 203-1112. The access
code is 594999.
INTERLEUKIN GENETICS
Interleukin Genetics is a biotechnology company focused on inflammation. The
company uses functional genomics to develop diagnostic, therapeutic and
nutraceutical products based on the genetic variations in people to help prevent
or treat diseases of inflammation. Interleukin's TARxGET (Translating Advanced
Research in Genomics into more Effective Therapeutics) programs focus on the
areas of cardiovascular disease, rheumatoid arthritis and osteoporosis and
include the development of tests to assess a person's risk for heart disease and
osteoporosis as well as a test to help doctors and patients choose the best
course of therapy for rheumatoid arthritis. These products will improve patient
care and produce better allocation of healthcare resources. In addition to its
research partnerships with numerous academic centers in the U.S. and Europe,
Interleukin's corporate collaborators include the leading healthcare
organizations, Kaiser Permanente and UnitedHealth Group. For more information
about Interleukin and its ongoing programs, please visit
http://www.ilgenetics.com
Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995)
including statements regarding the expectations about our future growth and
operating results, our ability to develop and commercialize our products,
entering into one or more strategic alliances on favorable terms with
well-funded partners and the sufficiency of our current resources to fund
operations into mid-October. Because such statements include risks and
uncertainties, actual results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, our ability to raise
necessary capital, complete clinical research and data analysis, meet
expectations about operating into mid-October, meet clinical studies' endpoints,
complete one or more strategic alliances, risk of market acceptance of our
products, risk of technology and products obsolescence, delays in development of
products, reliance on partners, competitive risks and those risks and
uncertainties described in our Form 10-Q for the quarter ended June 30, 2002, as
filed on August 19, 2002, and in other filings we have made with Securities and
Exchange Commission. We disclaim any obligation to update these forward-looking
statements.
For Interleukin Genetics:
Sharon Leibowitz
Interleukin Genetics, Inc.
(781) 398-0700
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERLEUKIN GENETICS, INC.
--------------------------
(Registrant)
Date: September 4, 2002 /s/ Fenel M. Eloi
----------------------------------
Fenel M. Eloi, Chief Operating Officer,
Chief Financial Officer, Treasurer and
Secretary and Treasurer